Lack of Funding for IBD Medication w/ Dr Richard Stein: April 11, 2022

Aotearoa has the third highest rate of inflammatory bowel disease, or IBD in the world, but essential medication is still unavailable due to Pharmac’s budget. Ustekinumab, otherwise known by its brand name – Stelara was approved by MedSafe in 2018 and is already funded in Australia. Crohn’s & Colitis NZ petitioned to get Stelara funded here last year - receiving 30,000 signatures. This led to Pharmac testifying before the petitions committee in October last year – where they said Stelara is needed but they still don’t have the funding. Sam Clark spoke to the Chair of Crohn’s & Colitis NZ, Dr Richard Stein about what has happened since.